A Prediction of Response of the Head and Neck of the U.S. Adult Military Population to Dynamic Impact Acceleration from Selected Dynamic Test Subjects.

Author(s):  
L. W. Schneider ◽  
B. M. Bowman ◽  
R. G. Snyder ◽  
L. S. Peck
2009 ◽  
Vol 135 (11) ◽  
pp. 1119 ◽  
Author(s):  
James P. Malone ◽  
Michael A. T. Gerberi ◽  
Syam Vasireddy ◽  
Larry F. Hughes ◽  
Krishna Rao ◽  
...  

2005 ◽  
Vol 133 (2) ◽  
pp. P50-P51 ◽  
Author(s):  
L DAVIES ◽  
H WELCH

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e17001-e17001
Author(s):  
F. Camacho ◽  
C. D. Mullins ◽  
V. Joish ◽  
J. Choi

e17001 Background: For the treatment of head and neck cancer (HNC), different modalities (chemotherapy, radiation, surgery, or chemoradiotherapy) can be used either independently or in combination with others. Information regarding real-world treatment pattern is limited. The purpose of this study was to identify common treatment pathways and associated costs. Methods: The study was performed using data from a large U.S. commercial managed care claims database. Adult subjects (≥18) diagnosed with HNC between January 1, 2006, to December 31, 2006, (index-period) were identified based on a pre-selected ICD-9-CM codes. All subjects were HNC diagnosis-naïve 12 months prior to their index dates (first date of HNC diagnosis) and followed for 12 months post index date. Treatment modalities were identified based on the Healthcare Common Procedure Coding System used in the U.S. Pathways were constructed by reflecting time of and between modality administration claims. Results: 6,570 subjects were identified. The average age was 61 years (±14.9) and 44% (n = 2869) were female. Midwest (31%) and east (31%) region had a higher (p < 0.01) representation, compared to south (20%) and west (18%). Only 2,257 subjects (34%) received some type of treatment modality and were categorized into 20 mutually exclusive treatment pathways. Of these, 82% (n = 1,843) received single modality, 18% (n = 398) received a combination of 2, and 0.7% (n = 16) received a combination of 3 modalities. Among single modality pathways, radiation (34%; n = 619) was most common, however, cheomoradiotherapy (26%; n = 485) had the highest average patient cost ($98,440). Within double modalities, radiation followed by chemotherapy (24%; n = 95) was most common, however, chemoradiotherapy followed by surgery (4%; n = 16) had the highest average cost ($146,374). Within triple modalities, surgery followed by radiation then chemotherapy (50%; n = 8) was most common and costly ($95,868). Conclusions: The most common treatment pathways one year post HNC diagnosis used a single modality; however, the average patient costs within multiple modalities were higher. Further study is required to investigate if these patterns are comparable to current guideline recommendation. [Table: see text]


2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e13084-e13084
Author(s):  
Melissa S. Oh ◽  
Renjian Jiang ◽  
Yuan Liu ◽  
Xiting Zhu ◽  
Nabil F. Saba ◽  
...  

e13084 Background: To compare the incidence, mortality, and survival of head and neck cancer (HNCA) in the U.S. Hispanic population to other racial/ethnic groups. Methods: Using the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, we compared the incidence and mortality of cancer of the oral cavity, pharynx, and larynx between the U.S. Hispanic population versus other racial and ethnic subgroups, as well as the annual percent change between 2000-2013. A comparative analysis for different groups stratified by age and sex was performed. Survival analysis was performed using Kaplan-Meier estimate and logistic regression analysis. Results: The incidence of oral cavity, pharyngeal, and laryngeal cancers were significantly lower in Hispanics compared to Non-Hispanics (p < 0.05). The incidence of laryngeal cancer decreased significantly at a rate of 2.5% annually (p < 0.05), while incidence of oral cavity and pharyngeal cancers remained unchanged in U.S. Hispanics. The mortality rate for oral cavity, pharyngeal, and laryngeal cancers in the U.S. Hispanic population were 1.4 per 100,000, 1.1 per 100,000, and 1.2 per 100,000 respectively. Mortality rates in Hispanics were significantly lower compared to Non-Hispanics (p < 0.05). Non-Hispanics Blacks had the highest HNCA-related mortality among all the compared groups. The mortality of HNCA was significantly declining annually in the U.S. Hispanic population (p < 0.05). Conclusions: The incidence and mortality of HNCA in the U.S. Hispanic population appears to be declining and is significantly lower compared to Non-Hispanics.


Cureus ◽  
2020 ◽  
Author(s):  
John J Pisquiy ◽  
Jordan T Carter ◽  
Andrew Chan ◽  
Nicholas Kusnezov ◽  
Adam Adler

2019 ◽  
Vol 44 (6) ◽  
pp. 516.e1-516.e7 ◽  
Author(s):  
John J. Pisquiy ◽  
Andrew G. Chan ◽  
Gautham Prabhakar ◽  
Nicholas Kusnezov ◽  
John C. Dunn

Sign in / Sign up

Export Citation Format

Share Document